J. R. Brown

Statistics

Publications

Citations

144

H-Index

Active since

2009

Affiliations

Dana-Farber Cancer Institute(Current)

J. R. Brown is an author at Dana-Farber Cancer Institute specializing in hematologic malignancy therapy, chronic lymphocytic leukemia therapy, and pi3k inhibitors.

Publications per year

2009–2013

Publications

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.

Steven Coutré, John C. Byrd, Richard R. Furman et al. · Journal of Clinical Oncology · 2011 · 69 citations

Medicine, Oncology, Pharmacology +16

Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

Richard R. Furman, John C. Byrd, Ian W. Flinn et al. · Journal of Clinical Oncology · 2010 · 43 citations

Medicine, Hematology, Pharmacology +12

Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies

Ian W. Flinn, John C. Byrd, Richard R. Furman et al. · Journal of Clinical Oncology · 2009 · 18 citations

Medicine, Oncology, Pharmacology +15

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

J. R. Brown, Bradley T. Messmer, Lillian Werner et al. · Haematologica · 2013 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

1–4 of 4